Incomplete Kawasaki Disease in a Child with COVID-19

We report a case of incomplete Kawasaki disease in a child who also tested positive for COVID-19. This case brings attention to the diverse presentation of coronavirus disease (COVID-19) disease in children.

A 5-year-old previously healthy African American male was admitted to the Pediatric inpatient floor with daily fever up to 39.4°C for 8 days. He had a history of rash, swelling (palms and soles), conjunctivitis, decreased appetite, diarrhea, dysuria, and abdominal pain. He had been treated with cefdinir for positive rapid streptococcal antigen test four days before, without clinical improvement. Physical examination showed dry, cracked, erythematous lips, non-exudative conjunctivitis, and bilateral shotty cervical lymphadenopathy but no rash. He had right scrotal edema and hydrocele suggestive of epididymo-orchitis on ultrasound. Clinically, he met the criteria for incomplete Kawasaki disease (KD).

Initial laboratory workup was significant for leukocytosis (white blood cells 40,000/cumm), anemia (hemoglobin 8 g/dL), thrombocytopenia (platelet count 104,000/cumm), elevated inflammatory markers (ESR 72 mm, CRP 25.6 mg/dL, procalcitonin 27 ng/mL, ferritin 1030 ng/mL), hyponatremia (serum sodium 121 meq/L), pyuria, hypoalbuminemia (2 g/dL), elevated liver enzymes (ALT 55 U/L), elevated troponins (0.06 ng/mL) and negative rapid influenza A/B antigens. Chest X-ray showed an enlarged cardiac silhouette (Fig. 1). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA was detected on RT-PCR from his nasopharyngeal swab. Echocardiogram showed a small global pericardial effusion but no ectasia, dilation, or aneurysm formation of coronary arteries (Fig. 2).

He was transferred to the pediatric intensive care unit because of hypotension. He received fluid boluses and intravenous immunoglobulin (IVIG) therapy was begun, which had to be discontinued because of recurring hypotension. He was briefly supported with high flow nasal cannula up to 10 liter for tachypnea and increased work of breathing, which was weaned-off. Once he was hemodynamically stable, IVIG infusion was resumed slowly at 5 grams over 10 hours (2-5 mL/minute) for 6 doses for a total dose of 30 grams (1.8 g/kg) [1] with a

**Fig. 1** Chest radiograph showing enlarged cardiac silhouette.

**Fig. 2** Apical four chamber view of a two dimensional echocardiogram of the patient showing a small global pericardial effusion. LA-Left Atrium; LV-Left ventricle; RA-Right atrium; RV-Right ventricle.
different formulation, after pre-medicating with
diphenhydramine and methylprednisolone (only for the
first dose) and started on medium-dose aspirin (~39 g/kg/ day).

The patient recovered on the pediatric floor with
supportive therapy for COVID-19 [3] and was
discharged after 6 days in the hospital. Hypotension with
elevated inflammatory markers in patients with KD are
the manifestations of KD shock syndrome (KDSS) [4].
Association between COVID-19 and KDSS [5] has been
speculated, but warrants further investigation.

Adverse effects to IVIG infusion commonly include
hypotension and anaphylactic reactions. This can be
treated with steroids and antihistamines as pre-
medication. However, there is a weak recommendation
regarding avoidance of steroids in patients with COVID-
19, with some indirect evidence of disease worsening [2].
Readers need to be aware of co-occurrence of Kawasaki
disease with COVID-19, and the associated management
issues.

Contributors- ER-drafted the manuscript; RS-supervised ER
and edited the manuscript; SS-helped with the
echocardiographic images and their labeling; PG-conceived the
idea of case report, supervised, edited and finalized the
manuscript.

Funding: none; Competing interests: None stated.
Published online: May 09, 2020; PII: S097475591600179.

REFERENCES
1. Son MBF, Newburger JW. Kawasaki disease. Pediatr Rev.
2018;39:78-90.
2. COVID-19 Treatment Guidelines Panel. Coronavirus
Diseases 2019 (COVID-19) Treatment Guidelines.
National Institutes of Health. Available from: https://www.
covid19treatmentguidelines.nih.gov/. Accessed May 8,
2020.
3. Chiotos K, Hayes M, Kimberlin DW, Jones SB, James
SH, Pinninti SG, et al. Multicenter Initial Guidance on Use
of Antivirals for Children With COVID-19/SARS-CoV-2.
J Pediatric Infect Dis Soc. 2020. Apr 22 [published online
ahead of print]. Available from: https://academic-
oup.com/jpids/advance-article/doi/10.1093/jpids/
piaa045. Accessed May 8, 2020.
4. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri
J, Tremoulet AH, et al. Recognition of a Kawasaki disease
shock syndrome. Pediatrics. 2009;123: e783-9.
5. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley
Segal J, el al. COVID-19 and Kawasaki disease: Novel
virus and novel case. Hosp Pediatr. 2020 Apr 7. https://
hosppeds.aappublications.org/content/early/2020/04/06/
hped.2020-0123.long. Accessed May 8, 2020.

Hyper-inflammatory Syndrome in
a Child With COVID-19 Treated
Successfully With Intravenous
Immunoglobulin and Tocilizumab

A previously well, eight-year-old boy presented with
fever, cough and throat pain. He was admitted to a local
hospital on day 4 of illness in view of high-grade fever
spikes. Investigations showed neutrophilic leukocytosis
(total white blood cell count 23,000/µL, Neutrophils
89%) with raised acute phase reactants (C-reactive
protein, CRP 120 mg/L). Chest X-ray showed right upper
and middle lobe infiltrates. Reverse transcriptase
polymerase chain reaction (RT-PCR) for severe acute
respiratory illness novel coronavirus 2 (SARS-CoV-2)
was negative. Treatment was empirically started with
ceftriaxone and azithromycin. Despite treatment for three
days, he continued to have high fever, worsening
respiratory symptoms and was referred to our hospital.

On arrival, he was alert, had respiratory rate of
50/min, intercostal retractions and was maintaining SpO2
in room air. He was febrile with tachycardia (HR 160/
min), hypotension (80/31 mm Hg), warm extremities and
a capillary refill time of 3 seconds. He was also noted to

Coronavirus disease (COVID-19) in children
appears to be largely a benign condition. However,
there are reports of children presenting significantly unwell across Europe
and USA in the last couple of weeks with a new
multisystem inflammatory syndrome [1]. We report a
child with COVID-19 who had overlapping features of
Toxic Shock Syndrome (TSS) and Kawasaki disease
(KD).